Symphonix Plans Vibrant SoundBridge Postmarket Surveillance Study
This article was originally published in The Gray Sheet
Executive Summary
Symphonix Devices will conduct an 18-month postmarket surveillance study of patients implanted with the Vibrant P and Vibrant D Soundbridge implantable middle-ear hearing devices. FDA approved the products on Aug. 31.
You may also be interested in...
InSound XT Gets FDA Nod To Become First Extended-Wear Hearing Aid
InSound Medical intends to create an installment payment plan for its InSound XT Series extended-wear disposable hearing aid, to be priced competitively with high-end digital aids in the $3,000 range
InSound XT Gets FDA Nod To Become First Extended-Wear Hearing Aid
InSound Medical intends to create an installment payment plan for its InSound XT Series extended-wear disposable hearing aid, to be priced competitively with high-end digital aids in the $3,000 range
Symphonix' Vibrant Soundbridge
Incorporation of advanced eight-channel digital signal processing component into the semi-implantable middle-ear hearing device gains FDA approval via PMA supplement Jan. 3. Increasing programming flexibility, the next-generation device follows the August 2000 approval of the first generation product (1"The Gray Sheet" Sept. 4, 2000, p. 7). A totally implantable device also is under development